<DOC>
	<DOCNO>NCT00036868</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy cyclophosphamide , methotrexate , fluorouracil use different way stop tumor cell divide stop grow die . Monoclonal antibody , trastuzumab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining chemotherapy trastuzumab may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine combination chemotherapy trastuzumab treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Trastuzumab Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare incidence clinical heart failure woman c-erbB2-positive metastatic breast cancer treat cyclophosphamide , methotrexate , fluorouracil combination trastuzumab ( Herceptin® ) . - Compare therapeutic activity regimen , term objective response rate , patient . - Compare duration response time progression patient treat regimen . - Compare toxic effect regimen patient . OUTLINE : This multicenter study . Patients receive CMF comprise cyclophosphamide orally day 1-14 IV day 1 8 methotrexate IV fluorouracil IV day 1 8 . Patients also receive trastuzumab ( Herceptin® ) IV 30-90 minute weekly begin day 1 . Treatment repeat every 4 week 8 course . Patients receive trastuzumab every 3 week absence disease progression , unacceptable toxicity , patient refusal . Patients follow every 8 week documentation disease progression initiation new anticancer therapy . Patients develop disease progression follow every 12 week . PROJECTED ACCRUAL : A total 66 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer cerbB2 positive ( 3+ overexpression HercepTest™ method ) primary tumor metastatic site At least 1 unidimensionally measurable target lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan Lesions irradiate precede 3 month use target lesion unless appear clearly progress since prior irradiation No bone lesion target lesion No contralateral breast cancer cerbB2positive cerbB2negative/unknown , status determine metastatic site No CNS metastases CT scan brain CSF cytology require neurologic symptoms present Hormone receptor status : Any estrogen progesterone receptor status PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Any status Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) Transaminases less 2.5 time ULN ( 5 time ULN liver metastasis present ) Renal : For patient age 18 69 : Creatinine great ULN For patient age 70 : Creatinine clearance normal Cardiovascular : LVEF normal MUGA echocardiogram No clinical heart failure Pulmonary : No malignancyassociated dyspnea rest No requirement supportive oxygen therapy Other : Not pregnant nursing No prior concurrent malignancy within past 5 year except adequately treat carcinoma situ cervix basal cell skin cancer No psychological , familial , sociological , geographical condition would preclude compliance study therapy followup schedule PRIOR CONCURRENT THERAPY : Biologic therapy : No prior anticerbB2 antibody , include trastuzumab ( Herceptin® ) No concurrent biologic therapy Chemotherapy : No 1 prior chemotherapy regimen metastatic breast cancer Prior combination cyclophosphamide , methotrexate , fluorouracil ( CMF ) allow adjuvant metastatic setting diseasefree interval completion CMF least 12 month Prior anthracyclines and/or taxanes allow At least 4 week since prior anthracyclines No prior cumulative dose doxorubicin 360 mg/m^2 No prior cumulative dose epirubicin 720 mg/m^2 No prior cumulative dose mitoxantrone 90 mg/m^2 No concurrent chemotherapy Endocrine therapy : More 2 week since prior hormonal therapy adjuvant metastatic set No concurrent hormonal therapy Radiotherapy : See Disease Characteristics No concurrent radiotherapy Surgery : Not specify Other : No concurrent anticancer therapy investigational drug No concurrent bisphosphonates start study enrollment except hypercalcemia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>